Ryuichi Mizuno

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 12

Top Topics

Editorial Comment

Vascular Endothelial Growth Factor

Tyrosine Kinase

Renal Cell Carcinoma

Top Venues

International journal of urology : official journal of the Japanese Urological Association

Japanese journal of clinical oncology

Medical oncology (Northwood, London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Taigo Kato, Ryuichi Mizuno, Hideaki Miyake
Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
Taigo Kato, Ryuichi Mizuno, Hideaki Miyake
Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. International journal of urology : official journal of the Japanese Urological Association (2024)
Taigo Kato, Ryuichi Mizuno, Hideaki Miyake
Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
Taigo Kato, Ryuichi Mizuno, Hideaki Miyake
Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
Taigo Kato, Ryuichi Mizuno, Hideaki Miyake
Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. International journal of urology : official journal of the Japanese Urological Association (2024)
Kohei Horiuchi, Shinnosuke Ikemura, Takashi Sato, Keitaro Shimozaki, Satoshi Okamori, Yoshitake Yamada, Yoichi Yokoyama, Masahiro Hashimoto, Masahiro Jinzaki, Ikuko Hirai, Takeru Funakoshi, Ryuichi Mizuno, Mototsugu Oya, Kenro Hirata, Yasuo Hamamoto, Hideki Terai, Hiroyuki Yasuda, Ichiro Kawada, Kenzo Soejima, Koichi Fukunaga
Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis. The oncologist (2023)
Minami Omura, Eiji Kikuchi, Keisuke Shigeta, Koichiro Ogihara, Kyohei Hakozaki, Satoshi Hara, Suguru Shirotake, Hiroki Ide, Shunsuke Yoshimine, Takashi Ohigashi, Ryuichi Mizuno, Mototsugu Oya
Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer. Japanese journal of clinical oncology 52 (4) (2022)
Tadatsugu Anno, Eiji Kikuchi, Keisuke Shigeta, Koichiro Ogihara, Keitaro Watanabe, Yoshinori Yanai, Kimiharu Takamatsu, Shintaro Hasegawa, Takeshi Masuda, Masafumi Oyama, Ryuichi Mizuno, Mototsugu Oya
Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery. Japanese journal of clinical oncology 51 (6) (2021)
Kimiharu Takamatsu, Ryuichi Mizuno, Yuto Baba, Yota Yasumizu, Nobuyuki Tanaka, Suguru Shirotake, Toshikazu Takeda, Shinya Morita, Kazuhiro Matsumoto, Takeo Kosaka, Hiroshi Asanuma, Masafumi Oyama, Shuji Mikami, Mototsugu Oya
On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma. International journal of clinical oncology 26 (8) (2021)
Shuji Mikami, Ryuichi Mizuno, Tsunenori Kondo, Nobuo Shinohara, Norio Nonomura, Seiichiro Ozono, Masatoshi Eto, Katsunori Tatsugami, Tatsuya Takayama, Hideyasu Matsuyama, Takeshi Kishida, Mototsugu Oya, null null
Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. Cancer science 110 (6) (2019)
Ryuichi Mizuno, Akira Miyajima, Taizo Hibi, Aya Masuda, Toshiaki Shinojima, Eiji Kikuchi, Masahiro Jinzaki, Mototsugu Oya
Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy. Medical oncology (Northwood, London, England) 34 (4) (2017)
Ryuichi Mizuno, Go Kimura, Satoshi Fukasawa, Takeshi Ueda, Tsunenori Kondo, Hidehiko Hara, Sunao Shoji, Kent Kanao, Hayakazu Nakazawa, Kazunari Tanabe, Shigeo Horie, Mototsugu Oya, null null
Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma. Cancer science 108 (9) (2017)